• Chu Matsuda, Megumi Ishiguro, Satoshi Teramukai, Yoshiki Kajiwara, Shoichi Fujii, Yusuke Kinugasa, Yoshihiko Nakamoto, Masanori Kotake, Yoshiyuki Sakamoto, Kiyotaka Kurachi, Atsuyuki Maeda, Koji Komori, Naohiro Tomita, Yasuhiro Shimada, Keiichi Takahashi, Kenjiro Kotake, Masahiko Watanabe, Hidetaka Mochizuki, Yoko Nakagawa, Kenichi Sugihara, and SACURA Study Group.
• Osaka General Medical Center, Department of Surgery, 3-1-56 Bandaihigashi, Sumiyoshi-ku, Osaka 558-8558, Japan. Electronic address: chu0710pinefield@aol.com.
• Eur. J. Cancer. 2018 Jun 1; 96: 54-63.

BackgroundEfficacy of adjuvant chemotherapy in patients with stage II colon cancer is still controversial. The SACURA trial is a randomised-controlled study evaluating the superiority of 1-year adjuvant treatment with oral tegafur-uracil (UFT) to surgery alone for stage II colon cancer.MethodsPatients were randomly assigned to the surgery-alone group or UFT group (UFT at 500-600 mg/day for 5 days, followed by 2-day rest, for 1 year). The primary end-point was disease-free survival (DFS). Target sample size was 2000, determined with one-sided alpha of 0.05, power of 0.9 and assumed hazard ratio (HR) 0.729.ResultsA total of 1982 patients (997 in the surgery-alone group and 985 in the UFT group) were analysed. Median follow-up was 69.5 months, median age was 66 years and for stage IIA/IIB/IIC, the distribution was 84%/13%/3%. The 5-year DFS rate was 78.4% in the surgery-alone group and 80.2% in the UFT group. The HR for DFS was 0.91 (95% confidence interval [CI], 0.75-1.10; p = 0.31); superiority of UFT was not demonstrated. Approximately 9% of patients experienced second cancers, which consist 40.7% of the DFS events. The 5-year relapse-free and overall survival rates of the surgery-alone and UFT group were 84.6% and 87.2% (HR, 0.82; 95% CI, 0.65-1.04) and 94.3% and 94.5% (HR, 0.93; 95% CI, 0.66-1.31), respectively. Subgroup analysis failed to disclose superiority in prognosis of adding UFT to the patients with risk factors for recurrence.ConclusionsSuperiority of 1-year adjuvant UFT over surgery alone was not demonstrated in stage II colon cancer. Patients with risk factors for recurrence did not benefit from UFT.Trial RegistrationClinicalTrials. Gov. #NCT00392899.Copyright © 2018 The Author(s). Published by Elsevier Ltd.. All rights reserved.

37 keywords...

hide…